In an exclusive interview to CNBC-TV18, Kiran Mazumdar Shaw of Biocon says that the breakup with Pfizer will not have any short-term impact on revenues for either company, but will reflect in the fourth quarter financials.
first published: Mar 13, 2012 10:50 am
A collection of the most-viewed Moneycontrol videos.
You are already a Moneycontrol Pro user.

